---
title: FCF Healthcare & Life Sciences Venture Capital Monitor - Europe - 12/2023 published - FCF Fox Corporate Finance GmbH
description: FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 12/2023”. The Monitor is a monthly published overview of venture capital trends in the European ... Read more
---

[Research ](https://www.fcf.de/en/resources/research)

# [FCF Healthcare & Life Sciences Venture Capital Monitor - Europe - 12/2023 published - FCF Fox Corporate Finance GmbH](https://www.fcf.de/en/resources/research/fcf-healthcare-life-sciences-venture-capital-monitor-europe-12-2023-published)

 Written by [FCFAdmin](https://www.fcf.de/en/resources/research/author/fcfadmin) | Jan 25, 2024 7:00:00 AM

FCF Fox Corporate Finance GmbH is delighted to publish the new “**FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 12/2023**”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

**As of the end of December 2023 we identify the following current VC trends in Europe:**

- In 2023, overall Life Sciences funding has reached EUR 8,949m
- Biotech received 42% of the total investment volume (+1% compared to the previous month)
- Oncology dominates as the top indication in Biotech
- Freya Biosciences (Denmark) has the highest transaction volume of EUR 35m in December, followed by Laza Medical (Switzerland) EUR 33m and Eligo Biosciences (France) EUR 30m
- The EIC Fund (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by Jeito (France) and Forbion (Netherlands)
- Top 5 Deals exceed EUR 130m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)

To access the full report, please click [here](https://www.fcf.de/resources/research/download-request-fcf-healthcare-life-sciences-research-series-europe?hsLang=en).

[View full post](https://www.fcf.de/en/resources/research/fcf-healthcare-life-sciences-venture-capital-monitor-europe-12-2023-published)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "FCFAdmin"
  },
  "dateModified" : "2025-11-11T15:52:18.148Z",
  "datePublished" : "2024-01-25T07:00:00Z",
  "headline" : "FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 12/2023 published",
  "image" : {
    "@type" : "ImageObject",
    "height" : 3563,
    "url" : "https://145785926.fs1.hubspotusercontent-eu1.net/hubfs/145785926/Website/Ressourcen/Healthcare_EU-Monitor_Shutterstock_2360267017_reduziert.jpeg",
    "width" : 9504
  },
  "mainEntityOfPage" : "https://www.fcf.de/en/resources/research/fcf-healthcare-life-sciences-venture-capital-monitor-europe-12-2023-published",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Research"
  }
}
```